Evidence map›Paper›PMID 37579113›Full record

ArticleJournal of addiction medicine

A Brief Screening and Assessment Tool for Opioid Use in Adults: Results from a Validation Study of the Tobacco, Alcohol, Prescription Medication, and Other Substances Tool.

Amanda M Bunting, Robert P Schwartz, Li-Tzy Wu, Aimee Wahle, Margaret Kline, Geetha Subramaniam, Jennifer McNeely

Abstract read
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amanda M BuntingFrom the New York University Grossman School of Medicine, New York, NY (AMB, JM); Friends Research Institute, Baltimore, MD (RPS); Duke University School of Medicine, Durham, NC (L-TW); The Emmes Company, Rockville, MD (AW, MK); and National Institute on Drug Abuse, Rockville, MD (GS).
Robert P Schwartz
Li-Tzy Wu
Aimee Wahle
Margaret Kline
Geetha Subramaniam
Jennifer McNeely

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
Clinical Trials Network: Mid-Atlantic Integrated Care Research CollaborativeUG1DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 2015 to 2019
$11.0M
Project-003UG1DA040317 · NIDA · DUKE UNIVERSITY · PI WU, LI-TZY · 2015 to 2019
$9.0M
The Lifespan/Brown Criminal Justice Research Program on Substance Use and HIVR25DA037190 · NIDA · MIRIAM HOSPITAL · PI CURT G BECKWITH · 2014 to 2026
$3.5M
NYU Training Program in Healthcare Delivery Science and Population Health ResearchT32HS026120 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORWITZ, LEORA, SCHWARTZ, MARK D · 2018 to 2023
$3.4M
MYCOBACTERIUM AVIUM-INTRACELLULARE IN AIDSZ01CL000013 · CLC · CLINICAL CENTER · PI MASUR, H · 1985 to 1986
–
AHRQ HHS T32 HS026120CLC NIH HHS 75N90019D00013NIDA NIH HHS 75N95021D00013NIDA NIH HHS R25 DA037190NIDA NIH HHS U10 DA013727NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA040317ORFDO NIH HHS 75N99019D00013
6 · The paper itself

Abstract

objectivesThis secondary analysis evaluated opioid-specific validation results of the Tobacco, Alcohol, Prescription Medication, and Other Substances (TAPS) tool for screening in primary care.

methodsThis study is a secondary data analysis of the TAPS validation study. Performance of the TAPS tool for screening for unhealthy opioid use (with a score of 1+ for heroin and/or prescription opioids representing a positive screen) was evaluated. Discriminative ability was examined in comparison with reference standard measures across the spectrum of unhealthy opioid use: timeline follow-back with and without oral fluid testing identifying past-month use and the modified Composite International Diagnostic Interview for past-year problem use, opioid use disorder (OUD), and moderate-severe OUD.

resultsIn a sample of 2000 primary care patients, 114 screened positive for opioids on the TAPS tool. With a TAPS cutoff equal to 1+, the TAPS accurately identified past-month use, problem use, any OUD, and moderate-severe OUD (sensitivities = 68%-85%, specificities = 97%-98%, area under the curve = 0.80-0.91). When past-month use was expanded to include timeline follow-back with oral fluid testing, accuracy declined (52% sensitivity [95% confidence interval, 43%-60%], 98% specific [95% confidence interval, 97%-98%]).

conclusionsWhile further testing in a larger population sample may be warranted, given their brevity, simplicity, and accuracy when self-administered, the TAPS opioid items can be used in primary care settings for a spectrum of unhealthy opioid use; however, self-disclosure remains an issue in primary care settings.

Indexed as

Opioid-Related DisordersPrescription DrugsTobacco Use DisorderAdultAnalgesics, OpioidEthanolHumansPrescriptionsAnalgesics, OpioidEthanolPrescription Drugs

Identifiers

PMID37579113
PMCPMC10404299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.